The incidence of clinically significant contrast-induced nephropathy following non-emergent coronary angiography

Catheterization and Cardiovascular Interventions

Volumn 71, Issue 7, 2008, Pages 879-885

  Weisbord, Steven D ^a   Hartwig, Kathryn C ^b   Sonel, Ali F ^b   Fine, Michael J ^b   Palevsky, Paul ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Angiography; Complications; Contrast media; Contrast induced nephropathy; Coronary; Mortality; Outcomes

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BICARBONATE; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOLDOPAM; HYPERTENSIVE FACTOR; INOTROPIC AGENT; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; IODOBENZOIC ACID DERIVATIVE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTRAST MEDIUM INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DIALYSIS; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; TRANSLUMINAL CORONARY ANGIOPLASTY; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; INCIDENCE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; TIME; UPREGULATION;

AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TRIIODOBENZOIC ACIDS; UP-REGULATION;

EID: 45849135257     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21565     Document Type: Article

References (42)

1. Taliercio CP, Vlietstra RE, Fisher LD, Burnett JC. Risks for renal dysfunction with cardiac angiography. Ann Intern Med 1986; 104:501-504.
2. Mehran R, Ashby DT. Radiocontrast-induced acute renal failure: Allocations and outcomes. Rev Cardiovasc Med 2001;2(Suppl 1): S9-S13.
3. Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int Suppl 2006: S11-S15.
4. Nikolsky E, Mehran R. Understanding the consequences of contrast-induced nephropathy. Rev Cardiovasc Med 2003;(4 Suppl 5): S10-S18.
5. Davidson CJ, Hlatky M, Morris KG, Pieper K, Skelton TN, Schwab SJ, Bashore TM, Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med 1989;110:119-124.
6. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int 1998;53:230-242.
7. Weisbord SD, Palevsky PM. Radiocontrast-induced acute renal failure. J Intensive Care Med 2005;20:63-75.
8. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-283.
9. Allison NL, Dubb JW, Ziemniak JA, Alexander F, Stote RM. The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin Pharmacol Ther 1987;41:282-288.
10. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003;348:491-499.
11. Briguori C, Airoldi F, D'Andrea D, Bonizzoni E. Morici N, Focaccio A, Michev I, Montorfano M, Carlino M, Cosgrave J, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): A randomized comparison of 3 preventive strategies. Circulation 2007;115:1211-1217.
12. Cacoub P. Deray G, Baumelou A, Jacobs C. No evidence for protective effects of nifedipine against radiocontrast-induced acute renal failure. Clin Nephrol 1988;29:215-216.
13. Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, Chung WY, Joo GW, Chae IH, Choi DJ, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: The RECOVER study: A randomized controlled trial. J Am Coll Cardiol 2006;48:924-930.
14. Kapoor A, Sinha N, Sharma RK, Shrivastava S, Radhakrishnan S, Goel PK, Bajaj R. Use of dopamine in prevention of contrast induced acute renal failure - A randomised study. Int J Cardiol 1996;53:233-236.
15. Khoury Z, Schlicht JR, Como J, Karschner JK, Shapiro AP, Mook WJ, Weber RJ. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 1995;15:59-65.
16. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-2782.
17. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, Trabattoni D, Fabbiocchi F, Montorsi P, Bartorelli AL. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003;349:1333-1340.
18. Mueller C, Buerkle G, Buettner HJ, Petersen J, Perruchoud AP, Eriksson U, Marsch S, Roskamm H. Prevention of contrast media-associated nephropathy: Randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. [see comments.]. Archives of Internal Medicine 2002; 162:329-336.
19. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004;291:2328-2334.
20. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, Hill JA, Winniford M, Cohen MB, VanFossen DB. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47:254-261.
21. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Gelormini JL, Labinaz M, Moreyra AE. Cardiac angiography in renally impaired patients (CARE) study: A randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007; 115:3189-3196.
22. Stone GW, McCullough PA, Tumlin JA, Lepor NE, Madyoon H, Murray P, Wang A, Chu AA, Schaer GL, Stevens M, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. JAMA 2003;290: 2284-2291.
23. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
24. Trivedi HS, Moore H, Nasr S, Aggarwal K, Agrawal A, Goel P, Hewett J, A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron 2003;93:C29-C34.
25. Rudnick M, Feldman H. Contrast-induced nephropathy: What are the true clinical consequences? Clin J Am Soc Nephrol 2008; 3:263-272.
26. Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Sonel AF, Fine MJ, Palevsky PM. Prevention, Incidence and Outcomes of Contrast-Induced Acute Kidney Injury, in press.
27. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000 (abstr);11 A0828.
28. Durham JD, Caputo C, Dokko J. Zaharakis T. Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-2207.
29. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, Pichard AD, Satler LF, Leon MB. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542-1548.
30. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047.
31. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489-1494.
32. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997; 103:368-375.
33. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
34. Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, Saul MI, Palevsky PM. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol 2006;17:2871-2877.
35. K/DOQJ clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
36. McCullough PA, Stacul F, Becker CR, Adam A, Lameire N, Tumlin JA, Davidson CJ. Contrast-Induced Nephropathy (CIN) Consensus Working Panel: Executive Summary. Rev Cardiovasc Med 2006;7:177-197.
37. Solomon R, Deray G. How to prevent contrast-induced nephropathy and manage risk patients: Practical recommendations. Kidney Int Suppl 2006:S51-S53.
38. Verhave JC, Fesler P, Ribstein J, du Cailar G, Mimran A, Estimation of renal function in subjects with normal serum creatinine levels: Influence of age and body mass index. Am J Kidney Dis 2005;46:233-241.
39. Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, Heiken JP, Lepanto L, Ni ZH, Nelson R. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: A double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006;41:815-821.
40. Recio-Mayoral A, Chaparro M, Prado B, Cozar R, Mendez I, Banerjee D, Kaski JC, Cubero J, Cruz JM. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: The RENO Study. J Am Coll Cardiol 2007.
41. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
42. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999;72:701-703.